Pamiparib

Pamiparib
Clinical data
Trade names	Partruvix
Other names	BGB-290
Legal status
Legal status	US: Investigational New Drug; Rx in China;
Identifiers
	IUPAC name (2R)-14-Fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one;
CAS Number	1446261-44-4;
PubChem CID	135565554;
DrugBank	DB14769;
ChemSpider	58805610;
UNII	8375F9S90C;
KEGG	D11426;
ChEMBL	ChEMBL4112930;
Chemical and physical data
Formula	C16H15FN4O
Molar mass	298.321 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F;
	InChI InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1; Key:DENYZIUJOTUUNY-MRXNPFEDSA-N;

Pamiparib, sold under the brand name Partruvix, is a pharmaceutical drug used for the treatment of various types of cancer. Pamiparib is a member of the PARP inhibitor drug class.^[1]

In China, it is approved for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, and primary peritoneal cancers previously treated with two or more lines of chemotherapy.^[2]

It is currently under investigation for the treatment of other forms of cancer.^[3]^[1]

References[edit]

^ ^a ^b Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al. (September 2020). "Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor". Neoplasia. 22 (9): 431–440. doi:10.1016/j.neo.2020.06.009. PMC 7350150. PMID 32652442.
^ Markham A (July 2021). "Pamiparib: First Approval". Drugs. 81 (11): 1343–1348. doi:10.1007/s40265-021-01552-8. PMID 34287805.
^ Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, et al. (September 2023). "Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial". British Journal of Cancer. 129 (5): 797–810. doi:10.1038/s41416-023-02349-0. PMC 10449784. PMID 37474720.

This oncology article is a stub. You can help Wikipedia by expanding it.

[Xiong-1] Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al. (September 2020). "Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor". Neoplasia. 22 (9): 431–440. doi:10.1016/j.neo.2020.06.009. PMC 7350150. PMID 32652442.

[2] Markham A (July 2021). "Pamiparib: First Approval". Drugs. 81 (11): 1343–1348. doi:10.1007/s40265-021-01552-8. PMID 34287805.

[3] Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, et al. (September 2023). "Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial". British Journal of Cancer. 129 (5): 797–810. doi:10.1038/s41416-023-02349-0. PMC 10449784. PMID 37474720.

[1]

[2]

[3]